3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Neoplasms
2
Meningioma
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Pemetrexed
4
pembrolizumab
3
Carboplatin
3
Vinorelbine
2
Gemcitabine
2
vistusertib
1
vandetanib
1
spartalizumab
1
sotorasib
1
sintilimab
1
olaparib
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
aumolertinib
1
Radiosurgery
1
Platinum
1
MLN 8237
1
Injections
1
Immune Checkpoint Inhibitors
1
Gefitinib
1
GC Temporary Stopping
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Cisplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Non-small Cell Lung Cancer Metastatic
×
vistusertib
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled